<code id='12702469CF'></code><style id='12702469CF'></style>
    • <acronym id='12702469CF'></acronym>
      <center id='12702469CF'><center id='12702469CF'><tfoot id='12702469CF'></tfoot></center><abbr id='12702469CF'><dir id='12702469CF'><tfoot id='12702469CF'></tfoot><noframes id='12702469CF'>

    • <optgroup id='12702469CF'><strike id='12702469CF'><sup id='12702469CF'></sup></strike><code id='12702469CF'></code></optgroup>
        1. <b id='12702469CF'><label id='12702469CF'><select id='12702469CF'><dt id='12702469CF'><span id='12702469CF'></span></dt></select></label></b><u id='12702469CF'></u>
          <i id='12702469CF'><strike id='12702469CF'><tt id='12702469CF'><pre id='12702469CF'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:comprehensive    Page View:57
          Adobe

          Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

          In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

          advertisement

          The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Cardiologists urge adding sexual orientation, gender identity to health records
          Cardiologists urge adding sexual orientation, gender identity to health records

          AdobeTherearemoreopenlyLGBTQ+peopleintheU.S.thanever,butlittleisknownabouttheuniquehealthchallengest

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          Congress must protect the remaining independent doctors

          AdobeMorethan100,000doctorshave leftprivate practice andbecomeemployeesofhospitalsandothercorporatee